Milorad Vujnic1, Stojan Peric2, Srdjan Popovic3, Nela Raseta1, Vesna Ralic2, Valerija Dobricic2, Ivana Novakovic2, Vidosava Rakocevic-Stojanovic2. 1. Faculty of Medicine, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and Herzegovina. 2. Neurology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Dr Subotica 6, 11 000, Belgrade, Serbia. 3. Endocrinology Clinic, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia.
Abstract
INTRODUCTION: The aim of this study was to assess the frequency and features of metabolic syndrome (MetS) in myotonic dystrophy type 1 (DM1). METHODS: We studied 66 DM1 patients (50% men, aged 41.9 ± 10.5 years, disease duration of 19.3 ± 8.6 years). New worldwide consensus criteria for MetS from 2009 were used. RESULTS: Components of MetS were present at the following frequencies: hypertriglyceridemia 67%; low HDL cholesterol 35%; hypertension 18%; central obesity 14%; and hyperglycemia 9%. MetS was present in 11 (17%) patients. The presence of MetS was not associated with patients' gender, age, disease severity, disease duration, or CTG repeat length (P > 0.05). Patients with MetS had significantly lower total SF-36 scores as a measure of quality of life in comparison to patients without MetS (P < 0.05). CONCLUSION: Although certain components of MetS were very frequent in patients with DM1, only 17% met the criteria for MetS.
INTRODUCTION: The aim of this study was to assess the frequency and features of metabolic syndrome (MetS) in myotonic dystrophy type 1 (DM1). METHODS: We studied 66 DM1 patients (50% men, aged 41.9 ± 10.5 years, disease duration of 19.3 ± 8.6 years). New worldwide consensus criteria for MetS from 2009 were used. RESULTS: Components of MetS were present at the following frequencies: hypertriglyceridemia 67%; low HDL cholesterol 35%; hypertension 18%; central obesity 14%; and hyperglycemia 9%. MetS was present in 11 (17%) patients. The presence of MetS was not associated with patients' gender, age, disease severity, disease duration, or CTG repeat length (P > 0.05). Patients with MetS had significantly lower total SF-36 scores as a measure of quality of life in comparison to patients without MetS (P < 0.05). CONCLUSION: Although certain components of MetS were very frequent in patients with DM1, only 17% met the criteria for MetS.
Authors: M Spaziani; A Semeraro; E Bucci; F Rossi; M Garibaldi; M A Papassifachis; C Pozza; A Anzuini; A Lenzi; G Antonini; A F Radicioni Journal: J Endocrinol Invest Date: 2019-11-30 Impact factor: 4.256
Authors: Sylvia Nieuwenhuis; Kees Okkersen; Joanna Widomska; Paul Blom; Peter A C 't Hoen; Baziel van Engelen; Jeffrey C Glennon Journal: Front Neurol Date: 2019-11-26 Impact factor: 4.003
Authors: Tiago Mateus; Filipa Martins; Alexandra Nunes; Maria Teresa Herdeiro; Sandra Rebelo Journal: Int J Environ Res Public Health Date: 2021-02-12 Impact factor: 3.390
Authors: Tiago Mateus; Idália Almeida; Adriana Costa; Diana Viegas; Sandra Magalhães; Filipa Martins; Maria Teresa Herdeiro; Odete A B da Cruz E Silva; Carla Fraga; Ivânia Alves; Alexandra Nunes; Sandra Rebelo Journal: Int J Environ Res Public Health Date: 2021-04-06 Impact factor: 3.390
Authors: Elizabeth M McNally; Douglas L Mann; Yigal Pinto; Deepak Bhakta; Gordon Tomaselli; Saman Nazarian; William J Groh; Takuhisa Tamura; Denis Duboc; Hideki Itoh; Leah Hellerstein; Pradeep P A Mammen Journal: J Am Heart Assoc Date: 2020-02-06 Impact factor: 5.501